Anchiano Therapeutics Ltd. and Chemomab Ltd. announced their entry into a definitive merger agreement pursuant to which the shareholders of Chemomab would become the majority holders of the combined company. Upon closing of the transaction, the combined company will assume the name Chemomab Therapeutics Ltd. and will be led by Chemomab's management team, headed by its co-founder and chief executive officer, Adi Mor, Ph.D. Neil Cohen, chief executive officer of Anchiano, will join the board of Chemomab at closing.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.841 USD | -3.33% | +3.83% | +64.90% |
05-06 | Oppenheimer Upgrades Chemomab Therapeutics to Outperform | MT |
04-10 | Transcript : Chemomab Therapeutics Ltd. - Special Call |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+64.90% | 12.36M | |
+9.42% | 114B | |
+11.84% | 104B | |
-14.15% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.16% | 17.89B | |
+7.99% | 14.28B | |
+36.24% | 12.55B |
- Stock Market
- Equities
- CMMB Stock
- News Chemomab Therapeutics Ltd.
- Anchiano Therapeutics Ltd. and Chemomab Ltd. Announce Executive Appointments